𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study

✍ Scribed by Martin Steinberg; Cynthia A. Munro; Quincy Samus; Peter V.Rabins; Jason Brandt; Constantine G. Lyketsos

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
70 KB
Volume
19
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objective

To investigate patient predictors of response to treatment of Major Depressive Episode (MDE) in Alzheimer's disease (AD).

Methods

Forty‐four outpatients with AD and MDE were randomized to receive either sertraline or placebo in a 12‐week placebo‐controlled, flexible‐dose clinical trial after a one week single‐blind placebo phase. All participants were evaluated for depression at entry using the 21‐item Hamilton Depression Rating Scale (HDRS) and the Cornell Scale for Depression in Dementia (CSDD). All subjects completed baseline neuropsychological testing. Caregiver burden and depression were also measured. The forty‐two subjects who completed at least one post‐enrollment follow‐up visit were included in the analysis.

Results

No baseline demographic, mood, neuropsychiatric, neuropsychological, or caregiver variable was a statistically significant predictor of response to treatment. There were trends for African‐American patients (p=0.07) and those with milder baseline agitation/aggression (p=0.08) to respond better.

Conclusion

No baseline characteristic assessed clearly predicts response to treatment of MDE in AD. A diverse population of depressed AD patients may thus respond similarly to the same treatment. Copyright © 2004 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Do treatment effects vary among differin
Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS-2)?
✍ Lea T. Drye; Barbara K. Martin; Constantine E. Frangakis; Curtis L. Meinert; Jac 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 388 KB

## Objective: To determine if the effect of sertraline in the depression in alzheimer's disease study - 2 (diads-2) differed in subgroups of patients defined by baseline depression criteria. ## Methods: Diads-2 was a randomized, parallel, placebo-controlled, multicenter trial designed to evaluate

Tianeptine versus fluoxetine in the trea
Tianeptine versus fluoxetine in the treatment of depression complicating Alzheimer's disease
✍ Tomasz M. Sobow; Marcin Maczkiewicz; Iwona Kloszewska 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB

Beeching, 1991) , sometimes transferring their own disquietude at such discussions with relatives on to the reluctance of relatives to talk about DNR issues. Perhaps, in the UK, we need to learn from many of our American colleagues who see it appropriate to formulate an advance directive that comb

An open-label study of escitalopram (Lex
An open-label study of escitalopram (Lexapro®) for the treatment of ‘Depression of Alzheimer's disease’ (dAD)
✍ V. Rao; J. R. Spiro; P. B. Rosenberg; H. B. Lee; A. Rosenblatt; C. G. Lyketsos 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 43 KB 👁 1 views

## Abstract ## Background Depression is a frequent neuropsychiatric complication of Alzheimer's Disease. ## Methods This study investigated the safety and effectiveness of escitalopram (LEXAPRO) for depression in AD (dAD) as defined by the NIMH consensus criteria in an 8‐week, open‐label treatme

Relationship of exercise and other risk
Relationship of exercise and other risk factors to depression of Alzheimer's disease: the LASER-AD study
✍ Ciaran Regan; Cornelius Katona; Zuzana Walker; Gill Livingston 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 2 views

## Abstract ## Background Depression is common in Alzheimer's disease (AD; 5–35%). It is associated with increased disability, cost of care and carer burden. Exercise is known to be associated with a lower prevalence of depression across the age range but little is known about its relationship to

Tolerability of switching from donepezil
Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease
✍ Gunhild Waldemar; Maritta Hyvärinen; Mette Krog Josiassen; Alex Kørner; Heikki L 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 44 KB 👁 1 views

This study investigates the tolerability, safety and efficacy of abrupt or stepwise switching from donepezil to memantine treatment in patients with moderate-to-severe Alzheimer's disease (AD). Outpatients (Table 1), !50 years, with dementia of the Alzheimer's type (DSM-IV-TR), MMSE 18 and receiving